- Home
- TOP vs MRSN Comparison
TOP vs MRSN Comparison
Compare TOP & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOP
- MRSN
- Stock Information
- Founded
- TOP 2015
- MRSN 2001
- Country
- TOP Hong Kong
- MRSN United States
- Employees
- TOP N/A
- MRSN N/A
- Industry
- TOP Investment Bankers/Brokers/Service
- MRSN Biotechnology: Pharmaceutical Preparations
- Sector
- TOP Finance
- MRSN Health Care
- Exchange
- TOP Nasdaq
- MRSN Nasdaq
- Market Cap
- TOP 44.1M
- MRSN 40.7M
- IPO Year
- TOP 2022
- MRSN 2017
- Fundamental
- Price
- TOP $1.24
- MRSN $0.39
- Analyst Decision
- TOP
- MRSN Strong Buy
- Analyst Count
- TOP 0
- MRSN 5
- Target Price
- TOP N/A
- MRSN $5.75
- AVG Volume (30 Days)
- TOP 76.3K
- MRSN 3.1M
- Earning Date
- TOP 07-29-2025
- MRSN 05-15-2025
- Dividend Yield
- TOP N/A
- MRSN N/A
- EPS Growth
- TOP N/A
- MRSN N/A
- EPS
- TOP N/A
- MRSN N/A
- Revenue
- TOP $2,730,890.00
- MRSN $34,006,000.00
- Revenue This Year
- TOP N/A
- MRSN N/A
- Revenue Next Year
- TOP N/A
- MRSN $1.30
- P/E Ratio
- TOP N/A
- MRSN N/A
- Revenue Growth
- TOP N/A
- MRSN N/A
- 52 Week Low
- TOP $1.00
- MRSN $0.26
- 52 Week High
- TOP $1.94
- MRSN $2.83
- Technical
- Relative Strength Index (RSI)
- TOP 48.66
- MRSN 53.73
- Support Level
- TOP $1.20
- MRSN $0.34
- Resistance Level
- TOP $1.47
- MRSN $0.38
- Average True Range (ATR)
- TOP 0.08
- MRSN 0.04
- MACD
- TOP -0.01
- MRSN 0.00
- Stochastic Oscillator
- TOP 20.69
- MRSN 59.03
About TOP TOP Financial Group Limited
TOP Financial Group Ltd is an online brokerage firm in Hong Kong specializing in trading local and overseas equities, futures, and options products. The Company generates brokerage commission income by enabling its customers to trade on multiple exchanges present globally. The company operates in only one segment which is the futures brokerage service.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.